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ABSTRACT 
Background: Human papillomavirus (HPV) infections are the most common sexually 
transmitted infections in the world today.  HPV has been identified as the cause of both cancer 
and genital warts.  A vaccine to prevent select types of HPV infection was developed and 
approved for males and females ages 9 to 26.  This vaccine has not been universally accepted by 
healthcare providers, parents, or the public and has lower vaccination coverage rates than other 
recommended vaccines for the same age group. Multiple studies addressing the knowledge, 
perceptions, and beliefs of providers and parents regarding the vaccine have taken place.  Only a 
few studies with the nursing profession are found in the literature and they do not look at the 
vaccine in regards to males.  Nurses are seen as one of the most trustworthy of professions.  
What nurses know, perceive and believe can impact both patients and those they come in contact 
with on an informal basis. 
Objective: The purpose of this study is to determine knowledge, beliefs, and perceptions 
of registered nurses about the human papillomavirus and associated vaccination for males. 
Methodology: This study took place in February of 2013 and used a descriptive 
correlational design with a cross-sectional survey.  The survey was administered online to alumni 
of the University of Central Florida (UCF) College of Nursing, members of the Theta Epsilon 
chapter of Sigma Theta Tau International Honor Society, and current graduate nursing students 
and faculty of UCF College of Nursing.  There were one hundred and twelve Registered Nurses 
that participated in the study.  
Findings: Knowledge of HPV varied among respondents.  The vast majority knew that 
HPV was a common sexually transmitted infection however less were knowledgeable on specific 
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information about the vaccine.  Less than eighty percent of study participants knew that the 
vaccine was available for both males and females. Close to ninety percent of respondents agreed 
that vaccinating males would be important to protect their future partners from complications 
associated with HPV, such as genital warts and cervical cancer, and to protect themselves from 
future complications, such as genital warts and cancers.  Participants with doctoral degrees 
possessed a significantly more favorable attitude (p<0.001) towards vaccine use in males than 
those with a bachelors degree.  
Conclusions: Nurses in this study were knowledgeable about specific HPV information 
but were less knowledgeable about the extent of infection seen in males or the availability of the 
vaccine for males. This study found inaccuracies and lack of knowledge among Registered 
Nurses that demonstrates the need for education about HPV and the associated vaccine.  While 
the attitudes of the respondents reflect favorably toward the vaccine, there is still a need for 
education among this population.  
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INTRODUCTION 
Human papillomavirus (HPV) infections are the most common sexually transmitted 
infections in the world today (Baseman & Koutsky, 2004).  Six million people in the United 
States are infected with HPV each year and approximately 20 million Americans are currently 
infected (CDC, 2012).  The majority of sexually active individuals will likely be exposed to HPV 
in their lifetime (Trottier & Franco, 2006) and HPV rates are especially high among sexually 
active young adults (Baseman & Koutsky, 2005).  While most HPV infections in individuals are 
eliminated by the body without clinical manifestations, HPV has been identified as a cause of 
both cancer and genital warts.  There are over 120 different types of HPVs and they are classified 
as either high-risk oncogenic or low-risk (Trottier & Franco, 2006).   
A vaccine to prevent HPV infection was developed by Merck & Co. and approved by the 
Food and Drug Administration (FDA) in 2006.  This vaccine, Gardasil ®, is a quadrivalent 
vaccine, developed to protect against four types of HPV (types 6, 11, 16, and 18) for prevention 
of cancer, precancerous or dysplastic lesions, and genital warts (Norman, 2006).  HPV types 6 
and 11 cause approximately 90% of genital warts (CDC, 2010b) and types 16 and 18 cause 
approximately 70% of cervical cancers worldwide (CDC, 2006).  Gardasil ® was originally 
approved for females, ages 9 to 26 (Norman, 2006), and was later approved for males ages 9 to 
26 for the prevention of genital warts caused by HPV types 6 and 11 (Sun, 2009).  Prior to 2010, 
Gardasil was approved for the prevention of cervical, vulvar, and vaginal cancers, with the 
prevention of anal cancer being added in 2010 (Sun, 2010). Another vaccine, developed by 
GlaxoSmithKline, named Cervarix ®, was approved by the FDA in 2009 for cervical cancer 
prevention (CDC, 2010a). Cervarix ® is a bivalent human papillomavirus vaccine that is directed 
against HPV types 16 and 18 and is only approved by the FDA for use in females. 
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The current recommendation for HPV vaccination by the Advisory Committee on 
Immunization Practices (ACIP) includes routine vaccination of males and females aged 11 to 12 
years with 3 doses of quadrivalent HPV vaccine (CDC, 2011a).  Vaccination is also 
recommended for females 13 to 26 years of age and males 13 to 21 years of age who have not 
been previously vaccinated or have not completed the full series, and for men through age 26 
who have sex with men or who have a weakened immune system because of HIV infection, 
medications, or other illness (CDC, 2013).  The American Academy of Pediatrics (2012) also 
recommends the vaccine for all 11 to 12 year old children as part of the adolescent immunization 
platform.  The ACIP’s recommendations for HPV vaccination are based on several aspects, 
including the safety and effectiveness of the vaccine, data on HPV epidemiology and age of 
sexual debut in the U.S., and the high probability of adolescents acquiring HPV within several 
years of debut (CDC, 2010b).  
Statement of Problem 
HPV has been identified as the cause of both genital warts and various cancers. About 
12,000 women in the U.S. get cervical cancer each year.  An additional 13,000 U.S. men and 
women get another form of HPV related cancer, including HPV associated vulvar, vaginal, 
penile, anal, and oropharyngeal cancers annually (CDC, 2012).  Genital warts are associated with 
a significant detriment to health related quality of life (Woodhall et al., 2008). HPV infection has 
also been linked to HIV acquisition (Houlihan et al., 2012). 
 According to the CDC (2011b) vaccination coverage among adolescents aged 13 through 
17 increased from 2009 to 2010 for three routinely administered vaccines [“meningococcal 
conjugate (MenACWY, 2 doses); tetanus, diphtheria, acellular pertussis (Tdap, 1 dose); and 
human papillomavirus (HPV, 3 doses)” (p. 1117)].  Of the three vaccines, HPV coverage saw 
 2 
less than half the increase observed for each of the other two vaccines.  Among adolescent 
females, HPV vaccine coverage increased from 44.3% in 2009 to 48.7% in 2010 for at least one 
dose, and from 26.7% in 2009 to 32.0% in 2010 for three doses, while only 1.4% of adolescent 
males in the same age group had received the HPV vaccine in 2010 (CDC, 2011b).  
Gardasil has been surrounded by controversy since before FDA approval in 2006 (Stein, 
2005).  While vaccination for both males and females is recommended by the ACIP, it has not 
being universally accepted by healthcare providers, parents or the public.  There has been a clash 
between social conservatives, who believed that immunizing to prevent a sexually transmitted 
disease could encourage sexual activity, and health advocates, who seek to use the vaccine 
aggressively in prevention efforts (Stein, 2005).  Conservative groups and some physicians are 
concerned that the vaccine would send subtle messages that condone sex before marriage or 
encourage risky sexual behavior.  Counters to this argument came from Alan M. Kaye, executive 
director of the National Cervical Cancer Coalition, in comparing the vaccine to a seat belt in 
saying, “just because you wear a seat belt doesn't mean you're seeking out an accident” (Stein, 
2005).   
Multiple studies address the knowledge, perceptions, and beliefs of providers and parents 
regarding the vaccine (Cates, Ortiz, Shafer, Romocki, & Coyne-Beasley, 2012; Daley & Crane, 
2010; Nandwani, 2010; Perkins & Clark, 2012; Weiss, Zimet, Rosenthal, Brenneman, & Klein, 
2010). Providers and parents have been hesitant of the vaccine’s implementation (Cates et al., 
2012; Daley & Crane, 2010; Perkins & Clark, 2012; Weiss et al., 2010).  Pediatric and family 
medicine providers are apprehensive about difficulty in discussing the vaccine with parents and 
are unaware of the health benefits of the vaccine for males (Perkins & Clark, 2012).  Parents 
 3 
worry about the cost of the vaccine as well as side effects, effectiveness and long-term safety 
(Cates et al., 2012).   
Additional studies have looked at the acceptance of the vaccine for males among parents, 
males, and providers (Liddon, Hood, Wynn, & Markowitz, 2010; Nandwani, 2010). 
Acceptability of the vaccine that protects against both cervical cancer and genital warts was high 
among male college students but lower in a community sample of males.  Support of vaccination 
among mothers of sons varied widely but was generally high.  Neither males nor parents saw 
prevention of cervical cancer for female partners as a motivating reason for HPV vaccination.  A 
repeated cited reason for declining HPV vaccination was the belief that there was no direct 
benefit for males (Liddon et al., 2010).  Provider’s overall recommendation for vaccination 
varied by age but was generally high, though there was a preference to vaccinate females over 
males (Liddon et al., 2010).   Additional factors influencing acceptance included sexual activity, 
perceived susceptibility or benefit of vaccination, perceived norms for HPV vaccination, and 
physician recommendation (Nandwani, 2010).  
For years, nurses have been regarded as the most trustworthy professionals (Gallup Poll, 
2012).  What nurses know, perceive and believe can impact not only patients but also persons 
they come in contact with on an informal basis.  Only a few studies addressing knowledge, 
perceptions, and beliefs about HPV have involved nurses (Brabin et al., 2011; Duval et al., 2009; 
Nganwai et al., 2008; Kahn et al., 2009; Stretch et al., 2009).  In the first year after vaccine 
approval for females, mothers who were also nurses were surveyed with the focus of determining 
intension of mothers to vaccinate their daughters.  This study found that the mothers’ intention to 
vaccinate a daughter was lower with a daughter <13 years than with an older daughter (Kahn et 
al., 2009).  
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Two studies in the UK assessed school nurses views on providing the vaccination without 
parental consent and factors limiting vaccine uptake (Brabin et al., 2011; Stretch et al., 2009).  
HPV vaccination in the United Kingdom (UK) has been provided to schools and administered by 
school nurses since 2008 (Stretch et al., 2009).  Vaccination uptake was affected by 
characteristics of the schools, schools’ attitudes toward health interventions, organizational 
problems, and the multiple roles of the school nurse (Stretch et al., 2009).  Brabin et al. (2011) 
looked at nurses’ views on providing the vaccination without parental consent and found that 
while girls were legally allowed to consent on their own, nurses would defer vaccination rather 
than vaccinate without parental consent.  
Two additional studies, that took place in Canada and Thailand, assessed nurses’ 
knowledge, attitudes, and beliefs about HPV (Duval et al., 2009; Nganwai et al., 2008).  
Nganwai et al. (2008) surveyed nurses in an urban hospital in Northeast Thailand and found that 
almost all nurses had a moderate knowledge related to cervical cancer/HPV and females but that 
there were still some major misunderstandings.  The authors recommended using strategies such 
as educational pamphlets, notices, and hospital announcements to increase nurses’ knowledge.  
Duval et al. (2009) assessed nurses’ knowledge, attitudes, and information needs as well as 
factors associated with willingness to recommend vaccination in Canada.  This study was funded 
by GlaxoSmithKline and found that most nurses supported HPV vaccination but recommended 
targeted educational efforts to ensure nurses’ involvement (Duval et al., 2009). Both studies 
emphasized the need for increased HPV vaccination efforts and recognized nurses to be a pivotal 
role in this process. Nganwai et al. (2008) described registered nurses “the most visible, frontline 
personnel providing health education to patients and the general population” (p. 15). Duval et al. 
(2009) discussed the need for support and acceptability by healthcare personnel in successfully 
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implementing a new vaccination program and chose nurses for this study “based on their 
decisive role in the promotion and realization of immunization programmes, as well as their 
known influence on patients’ decision to receive the vaccine” (p. 501). 
Additionally, a study assessing knowledge of, perceived susceptibility to, perceived 
seriousness of, and risk behaviors regarding HPV, and cervical cancer among female nursing 
students found a lack of knowledge and low perceived susceptibility among this population, 
which was similar to other studies among college women (Denny-Smith, Bairan, & Page, 2006).  
Researchers acknowledged the need knowledge about HPV for practitioners involved in the care 
with women and were surprised with the low knowledge levels among junior and senior nursing 
students in a baccalaureate program.  
Marketing of the vaccine was initially focused solely around HPV and cervical cancer in 
women (Herskovits, 2007).  However, the HPV vaccine for males received little attention when 
approved by the FDA (2009) until 2011 when it was recommended by the ACIP (Cates et al., 
2012).  As a result awareness is lower for use of this vaccine in males.  
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PURPOSE OF STUDY 
The purpose of this research study is to identify knowledge, beliefs and perceptions that 
may be barriers to achieving adequate vaccination rates of HPV vaccine in males through a 
survey of registered nurses.  Based on the history so far, potential barriers are provider and 
parent attitudes, social issues, and past marketing campaigns to increase awareness.  Findings of 
this thesis may promote development and implementation of interventions to increase acceptance 
of the vaccine. 
 
  
 7 
METHODS 
Design 
 This study used a descriptive correlational design.  The method was a cross-sectional 
survey. 
Subjects 
 Survey participants were recruited via an email letter of invitation.  Email lists used were 
alumni of the University of Central Florida (UCF) College of Nursing, members of the Theta 
Epsilon chapter of Sigma Theta Tau International Honor Society, and current graduate nursing 
students and faculty of UCF College of Nursing. Email addresses were obtained, with 
permission, from the UCF College of Nursing Alumni listserv and the Theta Epsilon chapter of 
Sigma Theta Tau International Honor Society.  The e-mail lists used assumed that the 
participants are graduates with a bachelors degree or higher in nursing, are registered nurses, and 
over 18 years old.  A total of 1,579 separate invitations were sent (Grad nurse – 817; MSN 
alumni – 224; Theta Epsilon – 538). 
It is possible that some nurses received multiple invitations to participate in the survey 
because some of the UCF College of Nursing alumni are also members of the Theta Epsilon 
chapter of Sigma Theta Tau International Honor Society and or current graduate nursing students 
or faculty.  However, once the survey was completed by one e-mail address it was closed for 
further attempts.  
Inclusion and Exclusion Criteria 
 Inclusion criteria: Registered Nurse, 18 years of age or older. Exclusion criteria: none.   
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PROCEDURES 
 Permission from the University of Central Florida’s Institutional Review Board was 
obtained. The survey was provided to study participants via e-mail inviting them to voluntarily 
participate in the study through a link to SurveyMonkey™ on February 20, 2013. The survey 
contained an explanation of the research. Consent was implied if they completed the survey and 
they were free to withdraw from the study at any point. Surveys that were not completed or 
submitted were not included. The online survey was left open and available for 2 weeks.   
Participants had the opportunity to be entered into a random drawing for one of 30 
Starbucks gift cards valued at $5 by including their e-mail address in the last question of the 
survey. Provision of this information was voluntary and could be left blank if the participant did 
not wish to provide this information or did not wish to receive the incentive. Emails provided 
were not used in any of the data analysis.   
 All data collected from the online survey was confidential and remained secure on the 
password protected survey website. Data was also downloaded into a separate Excel™ database 
and kept on a password protected computer and did not contain any identifiable information.  
Instruments 
 The study used a 39 question survey (Attachment A). The survey aimed to collect 
information about knowledge, beliefs, and perceptions of registered nurses of HPV and 
vaccination of males. The survey was adapted from two previously administered surveys to 
physicians (Daley & Crane, 2010; Weiss et al., 2010). Permission was given by the authors of 
these studies to utilize the questions and modify as needed for the difference in intended 
participants.  
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The survey contained 9 true/false questions about current understanding of HPV and 
HPV vaccine, 5 likert scale questions about current understanding of HPV in males, 8 likert scale 
questions regarding attitudes about recommending and vaccinating males patients with the HPV 
vaccine, and 9 questions regarding attitudes about the HPV vaccine in general. In addition, 8 
questions collected demographic information.  
Data Analysis 
For data analysis purposes demographic information on the following variables was 
transformed.  Employment was classified into 4 categories: hospital, community, education and 
other.  If the respondent had children or not was classified as yes or no and then if the child was 
male or not was a yes or no.  True/False/Don’t know responses were coded numerically as 1, 2 
and 0 respectively.  Likert scale responses were coded numerically from strongly disagree – 
strongly agree as 1-5.  There were five questions where the responses were flipped and these 
were recoded accordingly. Analysis of the survey included both descriptive and correlational 
statistics on the demographics and questions. In addition, T-tests or Chi-Squared tests were run, 
comparing age groups, education, ethnicity, or experience.  
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FINDINGS 
Sample Characteristics 
 One hundred and twelve (7.09% response rate) Registered Nurses participated in the 
study.  One survey was not included in the analysis because only the first few questions were 
completed for a final total of 111.  The majority of study participants were female (94.5%, 
n=103).  Participant ages ranged from 18 years old to older than 60 years with the majority 
falling between 45 and 60 years (44.1%, n=49).  The educational background of the participants 
ranged from bachelors degree to doctoral degree with the majority of participants having a 
Masters degree or higher (64.9%, n=72).  Half of the participants worked in a hospital setting 
(50.0%, n=56), others worked in a physician’s office (18.0%, n=20), and others in a variety of 
settings including but not limited to: public health, university setting, nursing home, and 
orthopedic clinic.  The participants experience as a nurse varied from fewer than 5 years of 
experience to 20 or more years of experience with the majority of participants having greater 
than 15 years of experience (62.2%, n=69).  The majority of participants were parents (68.5%, 
n=76).    
Knowledge, Understanding, and Attitudes 
Knowledge of HPV 
The vast majority of participants knew that HPV was a common sexually transmitted 
infection (96.4%).  Similarly but less known was that most cervical cancers are also caused by 
this virus (84.8%).  Comparably, ninety percent of the participants knew that most people with 
genital HPV infections did not have symptoms (90.2%).  Less than half of the participants knew 
that the incidence of HPV is not highest among women in their 30’s and many participants were 
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unsure about this item (39.3% false; 23.2% unsure).  Fifty nine percent of participants knew that 
sexually active adolescents did not need to be tested prior to HPV vaccination (58.6%).  Nurses 
with degrees were more likely to answer this question correctly than those with a master’s degree 
(p=0.045) or bachelors degree (p=0.037).  Nearly sixty percent of participants knew that men and 
women who have been diagnosed with HPV are not discouraged from getting the vaccine 
(59.8%) and respondents with doctoral degrees were more likely to answer this question 
incorrectly than those with less education. Fifty two percent knew that the HPV vaccine is not 
licensed for females older than 26 years old (52.3%) and almost eighty percent of participants 
were aware that there is a vaccine available for both males and females (78.4%).  Finally, a slight 
majority of participants thought that genital warts were caused by the same HPV types that cause 
cervical cancer, which is untrue (53.2%). In addition nurses with 10-14 years of experience got 
this question correct significantly more often then nurses with less than 5 years of experience (p 
= 0.047); those with 15-20 years of experience (p=0.037) and those with more than 20 years of 
experience (p = 0.021). 
Understanding of HPV in Males  
Participants agreed that “males are at risk for HPV infection” (71.4% strongly agreed and 
18.8% somewhat agreed), and that “genital and anal warts can cause serious physical, emotional, 
and financial consequences for males patients” (77.7% strongly agreed and 15.2% somewhat 
agreed). Respondents also agreed that “HPV infection is common in males” (46.8% strongly 
agreed and 31.5% somewhat agreed) and that “HPV infection may contribute to anal, penile, or 
head and neck cancers in males” (59.5% strongly agreed and 26.1% somewhat agreed). There 
was more uncertainty that “nearly all sexually active males have already been infected with HPV 
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by age 26,” however the majority of participants agreed with this statement (21.4% strongly 
agreed, 33.0% somewhat agreed, and 20.5% neither disagreed or agreed).  
In addition a total score was calculated based on each participant’s response to the 
statements about HPV in males.  A total score of 25 would indicate more correct knowledge of 
HPV in males, while a total score of 5 would indicate the least correct knowledge.  For this 
section, respondents with doctoral degrees had more correct knowledge towards the vaccine than 
those with less education, however, this difference was not statistically significant. Nurses with 
ten to fourteen years of experience had more correct knowledge on average towards the vaccine 
than any of the other experience groups, however, this difference was also not significant. Nurses 
over 60 years old had the most correct knowledge, on average, while nurses under 30 had the 
least correct knowledge of any age group, and this difference was significant (p=0.024). 
Attitudes About HPV Vaccine   
Some respondents were concerned that “vaccination against a sexually transmitted 
infection may encourage earlier or riskier sexual behavior,” however, most were not concerned 
(1.8% strongly agreed and 12.6% somewhat agreed). Seventy two percent of participants did not 
feel that the vaccine is too new and hasn’t been around long enough (51.4% strongly disagreed 
and 21.6% somewhat disagreed).  Similarly, two thirds of the participants were not concerned 
about the safety of the vaccine (45.0% strongly disagreed and 21.6% somewhat disagreed,) nor 
the efficacy of the vaccine (41.8% strongly disagreed and 23.6% somewhat disagreed).  Only 
four and a half percent of participants were opposed to HPV vaccination for moral or religious 
reasons (2.7% strongly agreed and 1.8% somewhat agreed).  Sixteen percent of participants 
reported to be “unaware that the vaccine is available for both males and females” (11.8% 
strongly agreed and 5.5% somewhat agreed). Nearly eighty percent of participants were 
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interested in the HPV vaccine for males (47.3% strongly agreed and 30.9% somewhat agreed).  
One third of the participants expressed ambivalence to being “more comfortable providing the 
HPV vaccine to males than females” (33.3% neither disagreed or agreed) and sixty one percent 
were no more comfortable providing the vaccine to males than females (45.9% strongly 
disagreed and 15.3% somewhat disagreed). Finally, participants ranged on their concern about 
the cost of the vaccine (31.2% strongly disagreed they were concerned about cost, 26.6% neither 
disagreed or agreed, and 22.0% somewhat agreed). 
 A total score for this section was also calculated based on each participant’s response to 
the questions with higher scores (max = 40) indicating the most favorable attitude towards the 
vaccine. Nurses with twenty or more years of experience had a more favorable attitude on 
average toward the vaccine than other experience groups. Doctoral degree holders possessed a 
more favorable attitude toward the vaccine than those with less education and persons ages 45 to 
60 had the most favorable attitude of any age group.  There were no statistically significant 
differences between groups based on experience or education. 
Attitudes About HPV Vaccine Use in Males  
More than ninety percent of participants agreed that males should be vaccinated against HPV to 
protect their future partners from cervical cancer and other consequences of HPV (73.6% 
strongly agree and 17.3% somewhat agree) as well as prevent females from getting infected with 
HPV in general (64.5% strongly agreed and 26.4% somewhat agreed).  Respondents also agreed 
that it would be important to vaccinate males to prevent them from getting genital and anal warts 
(53.7% strongly agreed and 30.6% somewhat agreed) and anal and penile cancers (61.3% 
strongly agreed, 30.6% somewhat agreed).  Participants disagreed that “we already vaccinate 
females against HPV so there is no need to vaccinate males as well” (81.1% strongly disagreed 
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and 15.3% somewhat disagreed).  Participants also disagreed that HPV causes too few cancers to 
make vaccinating males worthwhile (54.1% strongly disagreed and 29.7% somewhat disagreed).  
Likewise they disagreed with not vaccinating males because genital and anal warts can be 
managed in other ways (68.2% strongly disagreed and 22.7% somewhat disagreed). Similarly 
participants disagreed that “it’s too late to vaccinate against HPV if an adolescent male is already 
sexually active” (67.3% strongly disagreed and 22.7% somewhat disagreed).   
For this section persons under 30 years had the most favorable attitude towards 
vaccination of any of the age groups (NS) and doctoral degree holders possessed a significantly 
more favorable attitude towards the vaccine than those with a only a bachelors degree (p < 
0.001).  
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DISCUSSION OF FINDINGS 
 Nurses in this study were knowledgeable about specific HPV information, such as most 
cervical cancers are caused by HPV infection, that HPV is a relatively common sexually 
transmitted infection, and that most people with genital HPV infections are asymptomatic, 
however, there was significant lack of knowledge related to the types of HPV that cause genital 
warts or cervical cancer.  Respondents recognized that males are at risk for HPV infection and 
that infection can lead to serious complications in males but were less knowledgeable about the 
extent of infection seen in males or the availability of the vaccine for males.  
 The vast majority of respondents were interested in the HPV vaccine for males and were 
not concerned about safety of the vaccine, the efficacy of the vaccine, nor the cost of the vaccine.  
They also agreed that males should be vaccinated against HPV to prevent complications 
associated with HPV in both males and females, such as genital warts and cancers.  Participants 
did not agree that males should not be vaccinated because females are already being vaccinated 
or that vaccinating males is not worthwhile because HPV causes too few cancers.  
Findings from this study were similar to other research studies among nurses, however 
there were some notable differences. Registered Nurses surveyed in Thailand had a moderate 
level of knowledge about HPV but also had some major misunderstandings. Similar to this study, 
nearly ninety percent of respondents knew that HPV infection is usually asymptomatic, but only 
sixty percent were aware that almost all cervical cancers are caused by HPV infection compared 
to nearly eighty five percent of participants in this study. They also found age to have an inverse 
association with knowledge about cervical cancer and HPV, which was the opposite of this 
study, and found no association with marital status or education (Nganwai, et al., 2007).  
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Like the RNs in this study nearly three quarters of nurses surveyed in Canada recognized 
HPV infection as the cause of cervical cancer (Duval, et al., 2009).  However, one difference that 
was noted was that only nineteen percent of their respondents answered incorrectly about genital 
warts and cervical cancer being caused by the same types of HPV while this study had fifty three 
percent of respondents respond incorrectly to this question. Compared to a similar study of 
knowledge and attitudes among family physicians and pediatricians, participating nurses had a 
greater lack of knowledge on average than the physicians studied (Daley et al., 2010).  In 
particular, many of the nurses were unaware of specific guidelines related to vaccination, 
including that sexually active adolescents did not need to be tested prior to HPV vaccination, that 
men and women who have been diagnosed are not discouraged from getting the vaccine, that it is 
not licensed for women older than 26 years, and that the vaccine is available to both males and 
females. The lack of knowledge seen in the study was greater than expected since the majority of 
nurses sampled had a Masters degree or higher.     
 When comparing attitudes associated with HPV vaccination, there were also some 
differences with past studies.  In Thailand nearly forty percent agreed that HPV vaccination 
would increase propensity for sexual activity (Nganwai, et al., 2007) while this study found 
roughly fourteen percent agreed with this belief. Looking at attitudes associated with HPV 
vaccination among participants, when asked about vaccinating males against HPV related to 
preventing transmission to females, more respondents strongly agreed to the importance of 
vaccinating males “to protect their future partners from cervical cancer and other consequences 
of HPV” than “to prevent females from getting infected with HPV. When asked about 
vaccinating males against HPV for prevention HPV consequences in males, more respondents 
strongly agreed to the importance of vaccinating males to “prevent them from getting anal and 
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penile cancers” than “to prevent them from getting genital and anal warts”. It is also important to 
note that there were less “strongly agree” responses when asked about HPV vaccination for 
prevention of consequences associated with males than for prevention of consequences in their 
female partners. This was different than previous studies of vaccination acceptability, in which 
protecting future partners did not increase motivation for vaccination of males for either parents 
or males (Liddon et al., 2010). Previous studies on physician acceptability also found that the 
vaccine was being declined due to the belief that there was no direct benefit to males, which is 
opposite from the findings of this study in nurses (Liddon et al., 2010).  
 When looking at responses based on employment, age, education and experience, 
respondents with doctoral degrees had, on average, the most favorable attitudes toward the 
vaccination both in general and this was a very significant difference for vaccine use in males. 
Conversely, they also were more likely to answer incorrectly when asked about sexually active 
adolescents need for testing of HPV antibodies prior to HPV vaccination.  
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LIMITATIONS 
This study has several limitations. First, the response rate of participants was low 
(4.97%,). Normal response rates for research surveys are 52.7% with a standard deviation of 
20.4% (Yehuda & Holtom, 2008).  The sample used was another limitation. The study used a 
convenience sample that was limited to previous UCF graduates, current UCF faculty and 
graduate students, and members of Theta Epsilon chapter of Sigma Theta Tau International 
Honor Society of the greater Orlando area.  This group was mostly from the same geographic 
location and had similar educational backgrounds.  This sample was an underrepresentation and 
a more random and diverse sample would have been better and is therefore less generalizable.  
Another limitation of the study was the lower than average response rate which may indicate that 
attitudes of the respondents might differ from non-respondents introducing non-response bias.  
Lastly, the sample was mostly females, however, this is congruent to what is seen in nursing as a 
profession.  
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NURSING IMPLICATIONS 
 This study was the first of its kind to look at attitudes and knowledge of Registered 
Nurses related to HPV and associated vaccine specifically related to males.  The study found 
inaccuracies and lack of knowledge among nurses.  The results demonstrate a need for education 
about HPV and the associated vaccine, specifically for males, as vaccination rates are not as high 
as they are with other vaccinations. Education could take place as part of required continuing 
education for licensed nurses or in nursing program curriculum.   
 Marketing of the HPV vaccine was originally focused on girls and women.  This could 
contribute to the lack of knowledge about the vaccine availability for males.  Increased 
marketing in the public health arena would improve awareness among both nurses and the 
general public about the vaccine.   
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SUMMARY 
Six million people in the United States are infected with HPV each year and HPV 
infections are the most common sexually transmitted infections in the world today.  HPV has 
been identified as a cause of both genital warts and cancers.  HPV is also associated with 
increased risk for HIV acquisition (Houlihan et al., 2012). A vaccine that prevents the main types 
of HPV is approved in the US for use in males and females ages 9 to 26 and recommended as 
routine vaccination of males and females aged 11 to 12 years.  The vaccine was originally 
approved for use in females and was marketed as a vaccine to prevent cervical cancer. Current 
research finds limited acceptance of the vaccine among parents, patients, and physicians. 
Additionally, studies among nurses find moderate knowledge about HPV as a whole.   
Nurses in this study have lack of knowledge about HPV and the associated vaccine.  
Although attitudes reflect favorably toward the vaccine, there is a need for education about HPV 
and the associated vaccine among this population. This education could take place through 
continuing education, nursing school curriculum, or public health outlets.   
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